Peptides vs steroids vs GLP-1s: how the molecules differ
These three words often get used as if they name one family. They do not. "Peptide" and "steroid" are two different kinds of molecule. "GLP-1" is one particular peptide hormone, and it also names the receptor a whole class of newer compounds targets.
The short answers
- Are peptides steroids? No. A peptide is a chain of amino acids. A steroid is a compact ring structure built from cholesterol. They share no chemical backbone.
- Are peptides the same as GLP-1s? Only in one direction. GLP-1 is a peptide, but most peptides have nothing to do with GLP-1.
- Are all GLP-1 compounds peptides? Almost all. Semaglutide, tirzepatide and retatrutide are. Orforglipron is a small molecule that reaches the same receptor without being a peptide.
Side by side
| Peptides | Anabolic steroids | GLP-1 agonists | |
|---|---|---|---|
| Made of | A chain of amino acids | A four-ring carbon skeleton | Mostly modified amino acid chains |
| Example size | Glutathione: 307 Da | Testosterone: 288 Da | Semaglutide: about 4,100 Da |
| Where it usually acts | Receptors on the cell surface | Receptors inside the cell | The GLP-1 receptor on the cell surface |
| How the signal works | Receptor relays a message inward | Hormone and receptor alter gene activity directly | Receptor relays a message inward |
| Examples | BPC-157, oxytocin, GHK-Cu | Testosterone, nandrolone | Semaglutide, tirzepatide, retatrutide |
Da (dalton) is the unit of molecular mass. Peptides cover a wide range, from under 300 Da to several thousand.
What makes a steroid different
Steroids are fat-soluble molecules made from cholesterol, with a characteristic four-ring core. Testosterone and its synthetic relatives, the anabolic-androgenic steroids, are small and oily enough to pass through a cell membrane. Inside, they bind the androgen receptor, and that complex moves to the nucleus and changes which genes are switched on.
That route is the main contrast with most peptides, which generally cannot cross the membrane and instead signal from the surface.
Where GLP-1 fits
Glucagon-like peptide-1 is a natural hormone about 30 amino acids long, released from the gut. It lasts only minutes in the bloodstream because an enzyme called DPP-4 cuts it quickly. The research compounds and drugs built on it are mostly longer-lasting redesigns:
| Compound | Chain length | Receptors targeted |
|---|---|---|
| Semaglutide | 31 amino acids, with a fatty acid chain added | GLP-1 |
| Tirzepatide | 39 amino acids | GLP-1 and GIP |
| Retatrutide | 39 amino acids | GLP-1, GIP and glucagon |
| Orforglipron | Not a peptide (small molecule) | GLP-1 |
So "GLP-1" describes what a compound targets, while "peptide" describes what it is made of. That is why the two overlap without meaning the same thing.
Why the difference matters at the bench
| Peptides | Steroids | |
|---|---|---|
| Usual solvent | Water or buffer for many sequences | Organic solvents, because of low water solubility |
| Main stability concern | Water, proteases, oxidation, freeze-thaw | Generally more chemically robust |
| Typical supply form | Freeze-dried powder | Crystalline powder |
For peptide handling, see the reconstitution math and storage.
The rules treat them differently too
Anabolic steroids are controlled substances by name: Schedule III in the United States and Schedule IV in Canada. Peptides have no single legal category, so their status depends on the specific compound and the country.
Sports regulators also separate them. The World Anti-Doping Agency's Prohibited List covers anabolic agents in one class and peptide hormones in another, and it has named BPC-157 under its class for non-approved substances since 2022.
New to this? Start with what peptides are and how they work.
Sources
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol, 2008. Source
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab, 2018. Source
- Lau J, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. J Med Chem, 2015. Source
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Mol Metab, 2018. Source
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP and GLP-1 receptor agonist. Cell Metab, 2022. Source
- Wharton S, et al. Daily oral GLP-1 receptor agonist orforglipron. N Engl J Med, 2023. Source
- World Anti-Doping Agency. The Prohibited List. Source